GlassScriptPhysician profile
Rosemary Srisuk
NPI 1538326590
$17,420.19
in general payments reported to CMS, 2019-2025
34 companies · $3,649 in 2025
The $3,649 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,725 · 2022: $3,460 · 2023: $3,648 · 2024: $3,937 · 2025: $3,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,116.47 |
| Education | $118.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,739.35 | 2021-2025 | |
| Amgen INC. | $2,382.26 | 2022-2025 | Enbrel, Otezla, Krystexxa |
| Ucb, INC. | $2,083.81 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,240.31 | 2021-2025 | |
| Janssen Biotech, INC. | $1,087.93 | 2021-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $1,081.08 | 2021-2025 | Saphnelo |
| Genzyme Corporation | $879.85 | 2021-2025 | |
| Lilly USA, LLC | $681.74 | 2021-2024 | Taltz, Zepbound |
| Novartis Pharmaceuticals Corporation | $680.36 | 2021-2025 | |
| Glaxosmithkline, LLC. | $511.72 | 2021-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $381.37 | 2021-2025 | Orencia |
| Horizon Therapeutics Plc | $366.75 | 2021-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $295.99 | 2021-2025 | Strensiq |
| Mallinckrodt Hospital Products INC. | $286.61 | 2022-2025 | Acthar |
| Genentech USA, INC. | $274.98 | 2021-2024 | Actemra, Rituxan |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $256.45 | 2023-2025 | Idacio, Tyenne |
| Aurinia Pharma U.S., INC. | $201.14 | 2021-2025 | Lupkynis |
| Radius Health, INC. | $193.58 | 2021-2025 | Tymlos |
| Janssen Scientific Affairs, LLC | $148.21 | 2021-2024 | Tremfya |
| Kyowa Kirin, INC. | $114.69 | 2024-2025 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.50 | 2023-2025 | Cyltezo |
| Actelion Pharmaceuticals US, INC. | $56.70 | 2021-2025 | Opsumit, Uptravi |
| Ani Pharmaceuticals, INC. | $56.14 | 2022-2025 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $54.99 | 2022 | |
| Organon LLC | $50.00 | 2025 | Hadlima |
| Sobi, INC | $47.08 | 2024-2025 | |
| Octapharma USA, INC. | $39.24 | 2025 | Octagam Immune Globulin (Human) |
| Celltrion USA INC. | $32.07 | 2023-2025 | Yuflyma, Vegzelma |
| Pharming Healthcare, INC. | $30.66 | 2023 | Ruconest |
| Sandoz INC. | $22.72 | 2023 | Hyrimoz |
| Kiniksa Pharmaceuticals, LTD. | $19.70 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.67 | 2024 | |
| Ferring Pharmaceuticals INC. | $13.94 | 2023 | Euflexxa |
| Hikma Pharmaceuticals USA | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosemary Srisuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.